
Conference Coverage
about 21 hours ago
Managing Immunotherapy Side Effects in Cancer Careabout 23 hours ago
How AI Is Changing Cancer Care from Diagnosis to SurvivorshipLatest Content

Shorts










Podcasts
Videos
All News

Early detection and grade-based care help manage immunotherapy toxicities, with tailored approaches for skin, gastrointestinal and cardiac side effects.

New NCCN guidelines highlight personalized combo treatments and new options to help patients with advanced kidney cancer live longer, better lives.

A couple shares how caregiving, communication and perspective shaped their life after liver cancer.

AI is being used across cancer care for prevention, diagnosis, treatment, survivorship and end-of-life support, improving efficiency while posing deskilling and cognitive risks.

Amanda shares advice on resilience, self-advocacy and finding strength while navigating cancer survivorship and chronic GVHD.

FDA fast tracked ZW191 for platinum-resistant ovarian cancer, aiming to speed development of a potential new option for patients with limited treatments.

Black patients with early-stage lung cancer were less likely to receive curative treatment than White patients, despite all having Medicare coverage, study finds.

Learn about Ductal Carcinoma in Situ (DCIS), its diagnosis, treatment options and side effects. Empower yourself with information to navigate this journey with confidence.

Coverage from NCCN 2026 highlights global care delivery, younger patient needs, survivorship strategies and safer immunotherapy management.

Dr. Brittany Dulmage discusses how management of immune-related side effects can help patients stay on immunotherapy without compromising its effectiveness.

Global efforts in prevention, early detection and collaboration are improving cancer care access, but disparities persist based on where patients live.

Drs. Nunnery and McCann discuss the evolving HER2-positive breast cancer treatment paradigm in the latest episode of “Breast Cancer Briefing.”

FDA approves a PD-L1 test to help identify patients with esophageal or gastroesophageal junction (GEJ) cancer who may benefit from Keytruda.

Dr. Christopher H. Lieu highlights the rising cancer rate in younger adults and the need for more personalized, comprehensive care strategies.

New NCCN guidelines highlight how structured exercise and molecular profiling significantly reduce recurrence rates.






















